Truist Securities Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has maintained a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA), but lowered the price target from $6 to $5.
September 20, 2023 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has maintained a 'Buy' rating on Taysha Gene Therapies, but lowered the price target from $6 to $5.
The news is directly related to Taysha Gene Therapies. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100